Kidney Disease News and Research

RSS

Age of live donor has insignificant effect on long-term health of transplanted kidney

People with kidney failure may think that they're better off getting a new kidney from a young and spry donor, but a recent study indicates that for those over 39 years old, the age of a live donor—ranging from 18 to 64 years—has an insignificant effect on the long-term health of a transplanted kidney. The study's results appear in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

23 Mar 2012

FMBFarma granted exclusive rights to market Ampio's Zertane for PE in Brazil

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, and FBM Industria Farmaceutica Ltda, a member of the HOSPFAR Group that manufactures, imports and distributes pharmaceuticals in Brazil, today announced a license and distribution agreement providing FMBFarma exclusive rights to market Zertane in Brazil for the treatment of premature ejaculation.

22 Mar 2012

Aspirin may prevent cancer metastasis and halt its progress: Study

Aspirin has numerous benefits. It is already known that it may prevent cancer. Research shows it may also be an effective treatment for halting the disease once it has started. An analysis of five large trials of people who took a daily low dose aspirin showed that among those who developed cancer it reduced its spread to distant organs by 40 to 50 per cent.

21 Mar 2012

Ampio receives U.S. patent allowance for lead drug Ampion

Ampio Pharmaceuticals, Inc., a biopharmaceutical company conducting clinical trials on its three lead drugs, licensing distribution of these drugs and engaged in further drug development, today announced that it has received notice of allowance from the US Patent Office of an additional patent that complements and expands its anti inflammatory patent portfolio for its lead drug Ampion.

20 Mar 2012

Ampio completes partial planned interim review in Optina trial for diabetic macular edema

Ampio Pharmaceuticals, Inc., a biopharmaceutical company conducting clinical trials on its three lead drugs (Zertane completed two phase III studies, Ampion-completed proof of concept studies and Optina), licensing distribution of these drugs and engaged in further drug development, today announced that it completed the planned interim review of the first 50% of patients enrolled in the Optina trial for diabetic macular edema.

19 Mar 2012

3 million Australians to develop diabetes by 2025

According to the latest figures, one in three of today's young Australians will go on to develop diabetes. A new assessment of national health data released by Diabetes Australia today shows 1.5 million Australians currently have diabetes. It says the diabetes rate is likely to at least double in Australia over the next decade, and predicts 3 million people will have type 2 diabetes by 2025.

18 Mar 2012

Experts highlight latest advances in use of biomarkers in various diseases

Over the last few decades there has been an explosion in the discovery of biomarkers for diagnosis, disease monitoring, and prognostic evaluation. In the April issue of Translational Research, entitled "Biomarkers: New Tools of Modern Medicine," an international group of medical experts explores the promise and challenges of biomarker discovery and highlights the latest advances in the use of biomarkers in various diseases.

16 Mar 2012

Living-donor parathyroid gland transplant allows young woman to forgo 60 pills per day

Surgeons at the University of Illinois Hospital & Health Sciences System performed a rare living-donor parathyroid gland transplant to help a 22-year-old woman maintain normal calcium levels without the need for high-dose supplementation.

13 Mar 2012

HIPK2 regulator protein plays a crucial role in kidney fibrosis

Researchers from Mount Sinai School of Medicine have identified a regulator protein that plays a crucial role in kidney fibrosis, a condition that leads to kidney failure. Finding this regulator provides a new therapeutic target for the millions of Americans affected by kidney failure. The research is published in the March 11 issue of Nature Medicine.

12 Mar 2012

3SBio, DaVita partner to offer dialysis services in NE China

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD) today announced it has entered into an agreement with 3SBio Inc., a leading Chinese biotechnology developer of biopharmaceutical products, to establish a joint venture for providing dialysis treatments in northeastern China.

9 Mar 2012

Not all patients with CKD are destined for kidney failure

Not all patients with chronic kidney disease (CKD) are destined for kidney failure, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

9 Mar 2012

Some bone marrow cells could prevent rejection of transplanted kidney in recipients: Study

Researchers transplanted certain cells from the kidney donor’s bone marrow along with the new organ. Five of eight transplant recipients who tried the method so far were off immune-suppressing medication up to 2½ years later, the researchers reported Wednesday. The preliminary results were considered important enough to be published in the journal Science Translational Medicine even though the study still is under way, because the technique worked for patients who didn’t have well-matched or related donors.

8 Mar 2012

Diaverum takes an active role in 2012 World Kidney day

Diaverum, one of the world's leading renal care service providers, is taking an active role in today's World Kidney day. Through activities such as open door days at dialysis clinics, free kidney screening and blood pressure tests, Diaverum is increasing awareness for renal diseases and informing about possible prevention measures.

8 Mar 2012

Researchers identify key molecular player in mouse model of kidney disease

In findings that may lead to clinical trials of a promising new drug for kidney disease, researchers at Beth Israel Deaconess Medical Center (BIDMC) and their colleagues have identified a key molecular player and shown how a targeted experimental drug can reverse kidney damage in mouse models of diabetes, high blood pressure, genetic kidney disease, and other kidney injuries.

8 Mar 2012

Mysterious kidney disease 'devastating' Central America's Pacific Coast, AP reports

The Associated Press/Seattle Times reports on a "mysterious epidemic that is devastating the Pacific Coast of Central America, killing more than 24,000 people in El Salvador and Nicaragua since 2000 and striking thousands of others with chronic kidney disease at rates unseen virtually anywhere else."

7 Mar 2012

Metabolic syndrome predicts prevalence and incidence of CKD in elderly people

Elderly people with the metabolic syndrome-defined as having multiple risk factors associated with developing diabetes and heart disease-had an increased risk of chronic kidney disease, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

6 Mar 2012

AMAG fourth quarter total revenues decrease to $14.9 million

AMAG Pharmaceuticals, Inc. a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia, today reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2011. As of December 31, 2011, the company's cash, cash equivalents and investments totaled approximately $230 million.

5 Mar 2012

Concert commences dosing in CTP-499 Phase 2 clinical trial for diabetic nephropathy

Concert Pharmaceuticals, Inc. today announced the initiation of dosing in a Phase 2 clinical trial evaluating CTP-499, an investigational drug for the treatment of diabetic nephropathy, the leading cause of chronic kidney disease (CKD) in the US.

5 Mar 2012

Long-term data from Baxter's HyQ clinical study on PI

Baxter International Inc. today announced the presentation of additional long-term data supporting the clinical profile of HyQ, its investigational combination product for use in patients with primary immunodeficiencies.

From Baxter International Inc. 3 Mar 2012

Blood, urine markers can predict heart surgery patients at higher risk for worse AKI

Blood and urine markers can indicate which patients with an abrupt kidney injury following heart surgery will experience progressive kidney problems, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

2 Mar 2012